We have developed a vastly disruptive technology that analyses proteins and DNA with ultra-high performance, addressing a $10bn market.
Pharamaceutical companies face a tremendeus challenge to invest in new drugs, when the efficiency of R&D is very poor. There is a dire need for new generation analytical technologies that increase the efficiency of drug development. GMD addresses these needs by providing an ultra-potent, cost-effective technology based on a disposable plastic chip. Our customers are pharmaceutical and diagnostic companies, health care and research institututions.